The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma

被引:31
|
作者
Wu, Ning [1 ]
Du, Zunguo [2 ]
Zhu, Yongjun [1 ]
Song, Yang [1 ]
Pang, Liewen [1 ]
Chen, Zhiming [1 ]
机构
[1] Fudan Univ, HuaShan Hosp, Dept Cardiothorac Surg, 12 Middle Wulumuqi Rd, Shanghai 200040, Peoples R China
[2] Fudan Univ, HuaShan Hosp, Dept Pathol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
esophageal squamous cell carcinoma; PI3K/AKT/mTOR signaling pathway; PTEN; Prognosis; CANCER; MTOR; ACTIVATION;
D O I
10.1177/1533033818758772
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The abnormal phosphatase and tensin homolog expression and activated phosphoinositide-3 kinase/Protein kinase B (AKT)/mammalian target of rapamycin signaling pathway are involved in the progression of esophageal squamous cell carcinoma. By assessing the expression pattern of key components in the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin signaling pathway by immunohistochemistry in tumor and nontumor esophageal mucosa from patients with esophageal squamous cell carcinomas, we aimed to carefully explore the relationship between the various protein expressions and clinicopathological factors, as well as patient outcome. A total of 145 tumor and 145 nontumor samples from patients with esophageal squamous cell carcinoma, collected from HuaShan Hospital (Shanghai, China) were evaluated. Clinical characteristics, the targeted protein expressions (including phosphatase and tensin homolog, phosphoinositide-3 kinase, AKT, p-AKT, mammalian target of rapamycin, p-mTOR, p70S6 kinase 1, p-P70S6K1, elongation initiation factor 4E binding protein-1, and p-4E-BP1, and survival rate were analyzed. Among them, phosphoinositide-3 kinase, AKT, p-AKT, mammalian target of rapamycin, p-mTOR, elongation initiation factor 4E binding protein-1, p70S6 kinase 1, and p-P70S6K1 proteins were significantly upregulated in tumor tissue. Conversely, phosphatase and tensin homolog was largely downregulated in tumor tissue, notably in pT3-T4 tumors. Low expression of phosphatase and tensin homolog whereas high expression of mammalian target of rapamycin signaling components in tumors was closely related to the presence of lymph node metastases and advanced TNM stage (all P < .05). Moreover phosphatase and tensin homolog, mammalian target of rapamycin, and p70S6 kinase 1 were correlated with overall survival as well as p-mTOR was correlated with progression-free survival (all P < .05). Overexpression of mammalian target of rapamycin was proved to be an independent adverse prognostic factor for overall survival in esophageal squamous cell carcinomas. Our results suggest that the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin signaling pathway is activated in esophageal squamous cell carcinoma, with the low expression of phosphatase and tensin homolog and the high expression of the mammalian target of rapamycin component proteins (both total and phosphorylated) in tumor tissue. Our result might offer a new strategy for specific targeted therapy and prognostic assessment in esophageal cancer.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Targeting the PI3K/AKT/mTOR pathway in cutaneous squamous cell carcinoma
    Perry, Jay Ryan
    Thind, Amarinder Singh
    Minaei, Elahe
    Ryan, Emily
    Genenger, Benjamin
    Iyer, Gopal
    Martin, Carolan
    Ashford, Bruce
    Ranson, Andmarie
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 43 - 43
  • [2] PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy
    Luo, Qian
    Du, Ruijuan
    Liu, Wenting
    Huang, Guojing
    Dong, Zigang
    Li, Xiang
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway
    Ma, Lei
    Huang, Ke
    Zhang, Haibo
    Kim, Eungyung
    Kim, Hyeonjin
    Liu, Zhibin
    Kim, Chae Yeon
    Park, Kanghyun
    Raza, Muhammad Atif
    Kim, Kirim
    Yi, Junkoo
    Sung, Yonghun
    Ryoo, Zae Young
    Kim, Yong-Gun
    Kim, Myoung Ok
    [J]. JOURNAL OF CANCER, 2024, 15 (03): : 659 - 670
  • [4] Prognostic significance of PI3K/AKT/mTOR signaling pathway members in clear cell renal cell carcinoma
    Fan, Demin
    Liu, Qiang
    Wu, Fei
    Liu, Na
    Qu, Hongyi
    Yuan, Yijiao
    Li, Yong
    Gao, Huayu
    Ge, Juntao
    Xu, Yue
    Wang, Hao
    Liu, Qingyong
    Zhao, Zuohui
    [J]. PEERJ, 2020, 8
  • [5] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [6] Silencing UHRF1 Enhances Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inhibiting the PI3K/Akt/mTOR Signaling Pathway
    Hui, Beina
    Pan, Shupei
    Che, Shaomin
    Sun, Yuchen
    Yan, Yanli
    Guo, Jia
    Gong, Tuotuo
    Ren, Juan
    Zhang, Xiaozhi
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4841 - 4852
  • [7] Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
    Simpson, Daniel R.
    Mell, Loren K.
    Cohen, Ezra E. W.
    [J]. ORAL ONCOLOGY, 2015, 51 (04) : 291 - 298
  • [8] The Comprehensive Analysis of PI3K/AKT Pathway and miRNAs in Esophageal Squamous Cell Carcinoma
    Akagi, Ichiro
    Matsutani, Takeshi
    Ishibashi, Osamu
    Makino, Hiroshi
    Yoshida, Hiroshi
    Nomura, Tsutomu
    Hagiwara, Nobutoshi
    Maruyama, Hiroshi
    Yokoyama, Tadashi
    Hirakata, Atsushi
    Ueda, Junji
    Miyashita, Masao
    Uchida, Eiji
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S698 - S698
  • [9] MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway
    Qiao Guanen
    Shi Junjie
    Wu Baolin
    Wang Chaoyang
    Yang Yajuan
    Li Jing
    Li Junpeng
    Ning Gaili
    Wang Zhongping
    Wang Jun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 105 : 350 - 361
  • [10] Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway
    Zhang, Yanshan
    Chen, Weizuo
    Wang, Huijuan
    Pan, Tingting
    Zhang, Yinguo
    Li, Chao
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1209 - 1218